A Phase 2/3 interventional study of Metformin and Empagliflozin in Renal Insufficiency, Chronic, sponsored by Tanta University. Completed at 2 sites in Egypt. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-14.
Sponsored by Tanta University · Phase 2/3, Interventional, and Treatment
This randomized controlled trial aims at evaluating the efficacy and safety of the antidiabetics metformin versus empagliflozin on chronic kidney disease (CKD) progression in patients with CKD stages 2 or/and 3.
3,144 studies on the registry are indexed under Renal Insufficiency, Chronic; 704 are open to participants now.
This study's enrollment of 118 is above the median of 74 across 2,176 interventional studies indexed under Renal Insufficiency, Chronic.
Browse Renal Insufficiency, Chronic studies →Tanta University is the lead sponsor of 963 studies on the registry; 304 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
In this arm, patients with chronic kidney disease who meet study inclusion criteria will receive metformin 1000 mg PO daily added to their usual therapy.
Drug: Metformin · Other: Control
In this arm, patients with chronic kidney disease who meet study inclusion criteria will receive empagliflozin 10 mg daily PO added to their usual therapy.
Drug: Empagliflozin · Other: Control
In this arm, patients with chronic kidney disease who meet study inclusion criteria will receive their usual therapy.
Other: Control
Patients will receive metformin 1000 mg PO daily added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
Also known as: Biguanide
Patients will receive empagliflozin 10 mg daily PO added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
Also known as: Sodium glucose cotransporter-2 (SGLT2) inhibitor
Patients will receive their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
Change in estimated glomerular filtration rate (eGFR) values from baseline
This will be achieved by measuring the serum creatinine levels and then eGFR values will be calculated.
Time frame: Period of 12 months
Change in albumin or protein excretion values from baseline
This will be achieved by measuring the urinary albumin or protein:creatinine ratio from a spot urine test in a morning sample.
Time frame: Period of 12 months
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tanta University